GlassScriptPhysician profile
Kristi M Capaldi
NPI 1780999185
$6,726.30
in general payments reported to CMS, 2019-2025
27 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,824 · 2022: $1,049 · 2023: $692 · 2024: $1,432 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,853.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,564.86 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $837.43 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Orexo US, INC. | $679.39 | 2021-2025 | Zubsolv |
| Astrazeneca Pharmaceuticals LP | $555.19 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $481.68 | 2024-2025 | Caplyta |
| Gilead Sciences, INC. | $382.01 | 2021-2025 | |
| Uswm, LLC | $314.25 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $311.48 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $226.59 | 2021-2025 | Rexulti, Abilify Maintena |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.60 | 2024 | Lifevest |
| Glaxosmithkline, LLC. | $165.36 | 2022-2025 | Trelegy Ellipta |
| Lundbeck LLC | $150.85 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $150.42 | 2021-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $117.43 | 2021 | |
| Exact Sciences Corporation | $113.89 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $99.86 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.26 | 2022 | |
| Scilex Pharmaceuticals INC. | $41.37 | 2021 | |
| Pfizer INC. | $33.62 | 2021-2025 | |
| Braeburn INC. | $30.24 | 2024-2025 | Brixadi |
| Novo Nordisk INC | $27.33 | 2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $27.30 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.29 | 2021 | |
| Axsome Therapeutics, INC. | $17.17 | 2025 | Auvelity |
| Ibsa Pharma INC. | $15.83 | 2021 | |
| Indivior INC. | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Capaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.